We're Here for You!
The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.
Our May 1, 2021 IMF Patient & Family Webinar features exciting, late-breaking news about CAR T-cell and other promising therapies: Who are the likely candidates for these treatments and how can eligible patients access them? Dr. Durie will also share important updates on COVID-19 vaccines and variants. For newly diagnosed patients, “Myeloma 101” offers a simple introduction to what can be a complex disease, while a myeloma patient shares personal insights. Our expert panel will answer your questions on everything from what to do when myeloma comes back to how to stay safe during a COVID-19 summer.
Achieving a cure for myeloma is what every patient wants, and it is the ultimate goal of all myeloma researchers, says IMF Chairman Dr. Brian G.M. Durie. “We are learning more and more about the genetic and molecular mechanisms of resistance to current therapies.”
Calling it "a win for patients," the International Myeloma Foundation (IMF) welcomed FDA approval on March 26 of Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.
According to a press release from Sanofi, "The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy."
Need to stay informed about the news that impacts myeloma patients, but don’t have time to read everything out there? Then be sure to follow Dr. Brian Durie’s Week in Review blog. The leading myeloma expert and IMF Chairman of the Board drills down on a wide range of topics – from the latest myeloma research results to the environmental issues that offer insight into prevention. He sifts through the data to deliver the bottom line.
Last year marks the International Myeloma Foundation's (IMF) 30th anniversary, celebrating 30 years of scientific achievement with myeloma patient care at the heart of it all. What started in a garage with a borrowed typewriter is now the largest organization focused specifically on multiple myeloma. The IMF continues to push the needle forward toward a cure for myeloma with cure-focused trials and over 40 active research projects around the world. As IMF President and Founder Susie Durie says, "We are this close to the cure. I can see it on the horizon."
The support of loved ones allows us to continue to fund efforts to search for a cure. Check out how Fundraisers are helping in the fight against myeloma.
